Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Mebufotenin · GH001, NSC-88624

Small molecule · developed by GH Research Ireland

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Mebufotenin?

Mebufotenin (GH001, 5-MeO-DMT) is a small molecule administered by inhalation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GH001, NSC-88624, 5-Methoxy-N,N-dimethyltryptamine, 5-MeO-DMT
Drug type
Small molecule
Therapy area
Psychiatry
Developer
GH Research Ireland Limited
In trials of
GHRS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
X0MKX3GWU9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05800860 Phase 2 Treatment-resistant Depression Completed GHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Treatment-resistant Depression

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.